HC Wainwright Has Positive Outlook of SLN FY2025 Earnings

Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) – Equities researchers at HC Wainwright lifted their FY2025 EPS estimates for Silence Therapeutics in a research note issued to investors on Monday, November 10th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings of ($2.31) per share for the year, up from their prior forecast of ($2.34). HC Wainwright has a “Buy” rating and a $75.00 price objective on the stock. The consensus estimate for Silence Therapeutics’ current full-year earnings is ($1.77) per share. HC Wainwright also issued estimates for Silence Therapeutics’ Q4 2025 earnings at ($0.69) EPS, Q1 2026 earnings at ($0.54) EPS, Q2 2026 earnings at ($0.57) EPS, Q3 2026 earnings at ($0.57) EPS, Q4 2026 earnings at ($0.57) EPS, FY2026 earnings at ($2.25) EPS, FY2027 earnings at ($1.47) EPS, FY2028 earnings at ($1.38) EPS and FY2029 earnings at ($1.38) EPS.

Silence Therapeutics (NASDAQ:SLN) last issued its earnings results on Thursday, November 6th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.40) by ($0.05). The business had revenue of $0.16 million for the quarter, compared to analyst estimates of $3.28 million. Silence Therapeutics had a negative net margin of 254.25% and a negative return on equity of 61.76%.

Several other research firms have also weighed in on SLN. Chardan Capital reiterated a “buy” rating and issued a $35.00 price objective on shares of Silence Therapeutics in a research note on Friday, August 8th. Wall Street Zen upgraded Silence Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Silence Therapeutics in a research note on Wednesday, October 8th. Five research analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $32.60.

Silence Therapeutics Stock Up 0.1%

NASDAQ:SLN opened at $6.73 on Thursday. The firm has a market capitalization of $201.43 million, a PE ratio of -4.99 and a beta of 1.39. Silence Therapeutics has a 12-month low of $1.97 and a 12-month high of $16.90. The firm has a 50-day moving average price of $5.87 and a 200 day moving average price of $5.52.

Hedge Funds Weigh In On Silence Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. GAMMA Investing LLC grew its holdings in shares of Silence Therapeutics by 134.1% during the second quarter. GAMMA Investing LLC now owns 8,333 shares of the company’s stock worth $48,000 after purchasing an additional 4,773 shares during the last quarter. Beacon Pointe Advisors LLC acquired a new position in Silence Therapeutics during the 2nd quarter worth about $67,000. Evelyn Partners Investment Management Services Ltd grew its holdings in Silence Therapeutics by 481.3% during the 2nd quarter. Evelyn Partners Investment Management Services Ltd now owns 14,334 shares of the company’s stock worth $77,000 after acquiring an additional 11,868 shares during the last quarter. Massar Capital Management LP acquired a new position in shares of Silence Therapeutics during the second quarter worth approximately $115,000. Finally, Jump Financial LLC bought a new stake in shares of Silence Therapeutics during the first quarter valued at approximately $74,000. Institutional investors and hedge funds own 98.73% of the company’s stock.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.